Total Payments
$665.89
2024 Payments
$253.61
Companies
8
Transactions
33
Medicare Patients
906
Medicare Billing
$49,105
Payment Breakdown by Category
Food & Beverage$665.89 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $665.89 | 33 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $195.43 | 11 | $0 (2024) |
| Novo Nordisk Inc | $180.39 | 11 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $87.61 | 4 | $0 (2024) |
| Organon LLC | $82.93 | 1 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $45.79 | 2 | $0 (2023) |
| Amgen Inc. | $32.43 | 2 | $0 (2024) |
| CeQur Corporation | $27.87 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $13.44 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $253.61 | 14 | Lilly USA, LLC ($89.75) |
| 2023 | $281.72 | 12 | Lilly USA, LLC ($92.75) |
| 2022 | $114.78 | 6 | Novo Nordisk Inc ($70.75) |
| 2021 | $15.78 | 1 | Novo Nordisk Inc ($15.78) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Inflammation | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Obesity | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: VACCINES | ||||||
| 09/23/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Diabetes | ||||||
| 08/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: Diabetes | ||||||
| 07/08/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Diabetes | ||||||
| 04/23/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: PSYCHIATRY | ||||||
| 04/18/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Diabetes | ||||||
| 04/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: Diabetes | ||||||
| 03/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: PSYCHIATRY | ||||||
| 03/04/2024 | CeQur Corporation | CeQur Simplicity (Device) | Food and Beverage | Cash or cash equivalent | $27.87 | General |
| Category: Diabetes | ||||||
| 02/19/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Inflammation | ||||||
| 01/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: PSYCHIATRY | ||||||
| 01/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Diabetes | ||||||
| 12/06/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Diabetes | ||||||
| 10/16/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: PSYCHIATRY | ||||||
| 09/13/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Diabetes | ||||||
| 07/31/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Diabetes | ||||||
| 07/17/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Diabetes | ||||||
| 06/27/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Diabetes | ||||||
| 06/21/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Diabetes | ||||||
| 06/03/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/04/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Diabetes | ||||||
| 04/06/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: Obesity | ||||||
| 02/24/2023 | Organon LLC | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $82.93 | General |
| Category: ETONOGESTREL | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 270 | 396 | $61,905 | $14,861 |
| 2022 | 6 | 212 | 396 | $61,318 | $13,978 |
| 2021 | 4 | 192 | 305 | $49,622 | $12,379 |
| 2020 | 6 | 232 | 339 | $46,688 | $7,888 |
Total Patients
906
Total Services
1,436
Medicare Billing
$49,105
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 123 | $32,964 | $7,818 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 104 | $20,176 | $4,442 | 22.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 15 | 15 | $3,665 | $1,137 | 31.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 78 | 119 | $3,570 | $991.20 | 27.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 15 | 15 | $1,050 | $429.00 | 40.9% |
| 81003 | Automated urinalysis test | Office | 2023 | 15 | 20 | $480.00 | $44.00 | 9.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 64 | 124 | $33,232 | $7,261 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 104 | $20,176 | $4,836 | 24.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 15 | 15 | $2,830 | $1,054 | 37.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 16 | 16 | $1,120 | $438.72 | 39.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 50 | 112 | $3,360 | $332.31 | 9.9% |
| 81003 | Automated urinalysis test | Office | 2022 | 17 | 25 | $600.00 | $55.53 | 9.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 108 | $28,944 | $7,508 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 61 | 91 | $17,654 | $4,573 | 25.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 52 | 80 | $2,400 | $240.00 | 10.0% |
| 81003 | Automated urinalysis test | Office | 2021 | 20 | 26 | $624.00 | $58.50 | 9.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 105 | 176 | $34,144 | $5,585 | 16.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 26 | $6,968 | $1,031 | 14.8% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2020 | 12 | 12 | $1,927 | $732.00 | 38.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 64 | 94 | $2,820 | $279.09 | 9.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 14 | 14 | $421.00 | $222.18 | 52.8% |
| 81003 | Automated urinalysis test | Office | 2020 | 14 | 17 | $408.00 | $37.95 | 9.3% |
About Kimberly Todd, PA-C
Kimberly Todd, PA-C is a Surgical healthcare provider based in Tonganoxie, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2014. The National Provider Identifier (NPI) number assigned to this provider is 1982017182.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kimberly Todd, PA-C has received a total of $665.89 in payments from pharmaceutical and medical device companies, with $253.61 received in 2024. These payments were reported across 33 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($665.89).
As a Medicare-enrolled provider, Todd has provided services to 906 Medicare beneficiaries, totaling 1,436 services with total Medicare billing of $49,105. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Surgical
- Other Specialties Medical
- Location Tonganoxie, KS
- Active Since 06/04/2014
- Last Updated 10/27/2023
- Taxonomy Code 363AS0400X
- Entity Type Individual
- NPI Number 1982017182
Products in Payments
- MOUNJARO (Drug) $178.54
- REXULTI (Drug) $87.61
- NEXPLANON (Drug) $82.93
- Rybelsus (Drug) $70.33
- XARELTO (Drug) $45.79
- Otezla (Drug) $32.43
- Ozempic (Drug) $29.54
- Wegovy (Drug) $29.25
- CeQur Simplicity (Device) $27.87
- JARDIANCE (Drug) $16.89
- RYBELSUS (Drug) $15.78
- SHINGRIX (Biological) $13.44
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.